Terri Sebree

1.8k total citations
43 papers, 1.4k citations indexed

About

Terri Sebree is a scholar working on Psychiatry and Mental health, Pharmacology and Genetics. According to data from OpenAlex, Terri Sebree has authored 43 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 14 papers in Pharmacology and 9 papers in Genetics. Recurrent topics in Terri Sebree's work include Cannabis and Cannabinoid Research (12 papers), Epilepsy research and treatment (11 papers) and Schizophrenia research and treatment (11 papers). Terri Sebree is often cited by papers focused on Cannabis and Cannabinoid Research (12 papers), Epilepsy research and treatment (11 papers) and Schizophrenia research and treatment (11 papers). Terri Sebree collaborates with scholars based in United States, Australia and New Zealand. Terri Sebree's co-authors include Romeo T. Bachand, Timothy P. L. Smith, Karny Jacoby, Christopher P. Steidle, Sherwyn Schwartz, B. Wallin, Carol O’Neill, Steven D. Targum, Randall J. Mack and Kenneth B. Kashkin and has published in prestigious journals such as American Journal of Psychiatry, The Journal of Clinical Endocrinology & Metabolism and Neurology.

In The Last Decade

Terri Sebree

40 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Terri Sebree United States 16 627 505 419 220 132 43 1.4k
Timothy L. Holman United States 15 496 0.8× 111 0.2× 279 0.7× 152 0.7× 147 1.1× 22 896
Ladan Kashani Iran 19 242 0.4× 186 0.4× 203 0.5× 273 1.2× 54 0.4× 61 1.4k
Anna Gray United States 8 209 0.3× 219 0.4× 934 2.2× 324 1.5× 64 0.5× 10 1.4k
V. S. Fang United States 17 178 0.3× 132 0.3× 293 0.7× 197 0.9× 230 1.7× 50 912
Mariangela Pucci Italy 21 98 0.2× 513 1.0× 92 0.2× 323 1.5× 269 2.0× 54 1.2k
Firoozeh Raisi Iran 15 387 0.6× 142 0.3× 160 0.4× 142 0.6× 37 0.3× 49 1.1k
Rosa Catalán Spain 16 283 0.5× 258 0.5× 88 0.2× 209 0.9× 281 2.1× 29 866
Fu De Yang China 26 566 0.9× 83 0.2× 220 0.5× 398 1.8× 211 1.6× 53 1.7k
Shoko Tsuchimine Japan 18 276 0.4× 108 0.2× 69 0.2× 113 0.5× 130 1.0× 67 893
William E. Heydorn United States 19 253 0.4× 129 0.3× 61 0.1× 287 1.3× 176 1.3× 47 948

Countries citing papers authored by Terri Sebree

Since Specialization
Citations

This map shows the geographic impact of Terri Sebree's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terri Sebree with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terri Sebree more than expected).

Fields of papers citing papers by Terri Sebree

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terri Sebree. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terri Sebree. The network helps show where Terri Sebree may publish in the future.

Co-authorship network of co-authors of Terri Sebree

This figure shows the co-authorship network connecting the top 25 collaborators of Terri Sebree. A scholar is included among the top collaborators of Terri Sebree based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terri Sebree. Terri Sebree is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berry‐Kravis, Elizabeth, Randi J. Hagerman, Jonathan Cohen, et al.. (2025). Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study. Journal of Neurodevelopmental Disorders. 17(1). 69–69.
2.
Palumbo, Joseph, Brian F. Thomas, Dejan B. Budimirovic, et al.. (2023). Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment. Journal of Neurodevelopmental Disorders. 15(1). 1–1. 13 indexed citations
3.
Berry‐Kravis, Elizabeth, Randi J. Hagerman, Dejan B. Budimirovic, et al.. (2022). A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). Journal of Neurodevelopmental Disorders. 14(1). 56–56. 39 indexed citations
4.
5.
6.
Scheffer, Ingrid E., Joseph Hulihan, John A. Messenheimer, et al.. (2020). Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Open-label Clinical Trial (1631). Neurology. 94(15_supplement). 1 indexed citations
7.
8.
Sinclair, Duncan, Terri Sebree, Marcel O. Bonn‐Miller, et al.. (2019). Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism. Pharmacology Biochemistry and Behavior. 181. 93–100. 44 indexed citations
9.
Heussler, Helen, Jonathan Cohen, Natalie Silove, et al.. (2019). A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. Journal of Neurodevelopmental Disorders. 11(1). 16–16. 74 indexed citations
10.
Hunter, David J., et al.. (2018). Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis. Osteoarthritis and Cartilage. 26. S26–S26. 27 indexed citations
11.
Bonn‐Miller, Marcel O., Stan L. Banks, & Terri Sebree. (2017). Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. DOI: 10.1089/can.2016.0036. Cannabis and Cannabinoid Research. 2(1). 5–7. 9 indexed citations
12.
Pierce, Mark, Thomas Marbury, Carol O’Neill, et al.. (2009). Zelrix™: A Novel Transdermal Formulation of Sumatriptan. Headache The Journal of Head and Face Pain. 49(6). 817–825. 49 indexed citations
13.
Siegel, Steven J., et al.. (2007). A Unique Iontophoretic Patch for Optimal Transdermal Delivery of Sumatriptan. Pharmaceutical Research. 24(10). 1919–1926. 37 indexed citations
14.
Marbury, Thomas, et al.. (2003). Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim™, compared to AndroGel®. Biopharmaceutics & Drug Disposition. 24(3). 115–120. 61 indexed citations
15.
Steidle, Christopher P., Sherwyn Schwartz, Karny Jacoby, et al.. (2003). AA2500 Testosterone Gel Normalizes Androgen Levels in Aging Males with Improvements in Body Composition and Sexual Function. The Journal of Clinical Endocrinology & Metabolism. 88(6). 2673–2681. 335 indexed citations
16.
Zimbroff, Dan, John M. Kane, Carol A. Tamminga, et al.. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. American Journal of Psychiatry. 154(6). 782–791. 226 indexed citations
17.
Buchsbaum, Monte S., E. Hazlett, M. Mehmet Haznedar, Randall J. Mack, & Terri Sebree. (1996). Positron emission tomography in schizophrenic patients treated with sertindole and haloperidol. European Neuropsychopharmacology. 6. S4–109. 2 indexed citations
18.
Kammen, Daniël P. van, Joseph P. McEvoy, Steven D. Targum, David Kardatzke, & Terri Sebree. (1996). A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology. 124(1-2). 168–175. 135 indexed citations
19.
Stavchansky, S., James T. Doluisio, Catherine MacLeod, et al.. (1989). Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans. Biopharmaceutics & Drug Disposition. 10(3). 229–237. 1 indexed citations
20.
Stavchansky, S., James T. Doluisio, Catherine MacLeod, et al.. (1989). One year administration of almitrine bismesylate (vectarion) to chronic obstructive pulmonary disease patients: Pharmacokinetic analysis. Biopharmaceutics & Drug Disposition. 10(3). 247–255. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy L. Holman Breakdown of academic impact, for papers by Ladan Kashani Breakdown of academic impact, for papers by Anna Gray Breakdown of academic impact, for papers by V. S. Fang Breakdown of academic impact, for papers by Mariangela Pucci Breakdown of academic impact, for papers by Firoozeh Raisi Breakdown of academic impact, for papers by Rosa Catalán Breakdown of academic impact, for papers by Fu De Yang Breakdown of academic impact, for papers by Shoko Tsuchimine Breakdown of academic impact, for papers by William E. Heydorn
Rankless by CCL
2026